The extracellular matrix (ECM) is a complex network of molecules secreted by cells, which is essential for providing structural support and facilitating cell processes including adhesion, migration and survival. Tenascin-C is an immunomodulatory ECM protein that exhibits limited expression in healthy tissues, but is transiently elevated at sites of tissue injury, and is persistently expressed in chronic inflammatory diseases and tumours. Alternative splicing of 9 of tenascin-C's fibronectin type III-like domains (FnIII- A1, A2, A3, A4, B, AD2, AD1, C and D) generates enormous diversity in form; yielding 511 possible isoforms. Post-transcriptional modification of tenascin-C has been studied in cancer and during development where disease and tissue specific isoforms exhibit distinct adhesive, migratory and proliferative effects. However, little is known of how tenascin-C is expressed or alternatively spliced during inflammation. This study characterises inflammation and disease specific tenascin-C isoforms made by immune cells and fibroblasts, and investigates their functional relevance. Biosynthesis and alternative splicing of tenascin-C was examined using standard curve qPCR, ELISA, Western blot and confocal immunocytochemistry in resting and activated primary human immune cells, dermal fibroblasts, and in synovial fibroblasts isolated from healthy controls and from osteoarthritis (OA) and rheumatoid arthritis (RA) patients. Based on these data, three recombinant proteins comprising FnIII domains AD2-AD1, B-C-D and B-AD2-AD1-C-D were cloned, expressed and purified, and their impact on cell behaviour including adhesion, morphology and migration was assessed. Basal tenascin-C expression was lower in myeloid and lymphoid cells than fibroblasts, and was induced in all following inflammatory stimulation. Tenascin-C expression was elevated in disease with RA and OA synovial fibroblasts containing higher levels than healthy controls. Alternative splicing following cell activation was cell-type specific: all FnIII except AD2 and AD1 were upregulated in dendritic cells and macrophages, in T-cells all FnIII remained unchanged with FnIII A1 absent; and no change in splicing was observed in activated dermal fibroblasts. Normal and OA synovial fibroblasts exhibited similar tenascin-C splicing patterns, but FnIII B and D were specifically elevated in RA. Functional analysis revealed differences in the adhesion, morphology and migration of myeloid cells and dermal fibroblasts cultured on FnIII AD2-AD1, B-C-D, B-AD2-AD1-C-D and full length tenascin-C substrates; FnIII B-C-D promoted MDDC migration while B-AD2-AD1-C-D promoted fibroblast adhesion, compared to full length tenascin-C. For the first time, this study reveals differences in tenascin-C biosynthesis and alternative splicing by immune cells and fibroblasts following activation with inflammatory stimuli; and starts to reveal how alternative splicing of tenascin-C may influence the behaviours of both stromal and immune cells types during inflammation and in inflammatory diseases.

Insulin like Growth Factor Binding Proteins (IGFBPs) 1 to 6 have important physiological functions of regulating half life and bioavailability of Insulin like Growth Factors (IGFs). Consequently, these have been known to play important roles in embryonic development, postnatal growth and disease conditions like cancer. However, the physiological roles of IGFBPs are diverse and not restricted only to the IGF regulation. These molecules are found to be tumor suppressors or promoters depending on the physiological contexts. IGFBP-2 has been established as a tumor promoter and found to be unregulated in several cancers including breast, ovarian, prostate cancer and glioblastoma (GBM). Various in vitro and in vivo studies have convincingly demonstrated the role of IGFBP-2 in inducing tumor cell proliferation, migration, invasion and chemoresistance. Increased plasma and tissue levels of IGFBP-2 have been associated with poor clinical outcome with respect to patients’ response to the therapy, relapse and overall survival. Various studies so far have demonstrated the role of IGFBP-2 in promoting glioma cell proliferation, migration, invasion, chemoresistance and determining stamens of GICs (Glioma Initiating Cells). However, the exact mechanisms underlying these functions remain unknown. Apart from being a diagnostic and prognostic indicator, IGFBP-2 has also been proposed as a therapeutic target. Therefore it is essential to understand mechanistic insights into pro-tumorigenic functions of IGFBP-2. Apart from the conventional function of regulating IGFs, IGFBP-2 has been shown to have several IGF independent functions. In a previous study, we reported IGFBP-2 as an upstream regulator of β-catenin signaling pathway in breast cancer. Interestingly, this study linked the association of higher expression of IGFBP-2 and β-catenin with the lymph node metastasis status of breast cancer. β-catenin signaling has been considered as one of the most important pro-tumorigenic pathways in several cancers including glioblastoma. Considering the importance of IGFBP-2 and β-catenin signaling pathways in glioblastoma, it becomes important to evaluate regulation of β-catenin activity by IGFBP-2 in glioma and address its clinical relevance. With this aim, the objectives of this study are,  To study mechanism of IGFBP-2 mediated regulation of β-catenin signaling in glioma cells and prognostic significance of IGFBP-2 and β-catenin expression in GBM tissues.  Isolation of human single chain variable fragment (scFv) against IGFBP-2 and its characterization as an inhibitor for IGFBP-2 pro-tumorigenic functions. Towards this, we established stable IGFBP-2 knockdown U251 cell line and IGFBP-2 over expressing LN229 and U87 cell lines. IGFBP-2 modulation in these glioma cell lines did not alter the rate of proliferation but there was a significant effect on cellular migration and invasion. In case of U251 cell line, there was a significant decrease in the intracellular levels of β-catenin while in IGFBP-2 over expressing cell lines there was a marked increase in intracellular β-catenin suggesting that IGFBP-2 is involved in the regulation of β-catenin in these cells. It was observed that this regulation of β-catenin was not because of its transcriptional regulation or regulation of canonical Wnt ligands Wnt1, Wnt2 and Wnt3a. To further delineate the pathway and understand the mechanism behind regulation of β-catenin, upstream regulators of β-catenin were analyzed. GSK3β is an important negative regulator of β-catenin which primes it for ubiquitination and proteasomal degradation. Phosphorylation of GSK3β at Ser9 position renders this enzyme inactive. In our study, it was observed that there was a significant downregulation of p-GSK3β in U251 cells with IGFBP-2 knockdown and upregulation in IGFBP-2 over expressing cell lines. Overexpression of IGFBP-2 in LN229 and U87 cell lines resulted in considerable decrease in the GSK3β mediated phosphorylation of β-catenin. This study unequivocally established that regulation of β-catenin by IGFBP-2 is via inactivation of GSK3β. Furthermore, regulation of GSK3β was found to be due to action of FAK following binding of IGFBP-2 to integrins. The expression pattern of IGFBP-2 and β-catenin protein in the tumor tissues of 112 GBM patients was studied and its correlation with patient survival was analysed. In this analysis it was observed that co-expression of IGFBP-2 and β-catenin is a strong predictor of patient prognosis. These results further implied the importance of understanding IGFBP-2 and β-catenin association in GBM pathology. One of the interesting observations in our study is that, not only full length IGFBP-2 protein but also C-terminal domain of IGFBP-2 was sufficient to regulate β-catenin and other IGFBP-2 mediated functions. This strongly asserts the importance of C-terminal region of IGFBP-2 as a tumor promoter. Towards an attempt to develop an inhibitor for IGFBP-2 actions, we screened a human single chain variable fragment (scFv) library using phage display technique. From this screening, one scFv (B7J) was identified which was a binder of full length IGFBP-2 as well as C-terminal domain of IGFBP-2. This scFv showed inhibition of IGFBP-2-cell surface interaction and also efficiently inhibited IGFBP-2-induced signaling pathways like ERK, FAK and GSK3β/β-catenin. B7J treatment also neutralized regulation of IGFBP-2 transcriptional targets like MMP2 and CD24. Gelatin zymography indicated the ability of B7J to decrease matrix metalloprotease activity in the conditioned medium of glioma cells. These effects ultimately reflected on the IGFBP-2-induced cellular migratory and invasive behaviour which was largely abrogated by B7J scFv treatment. Considering the therapeutic importance of scFvs because of their small size, better tumor penetration and tumor retention capacity than full length antibody molecules, such kind of strategy could be of great importance in the management of GBM. Altogether, this study provides a mechanistic insight of IGFBP-2 mediated actions involving integrin/FAK/GSK3β/β-catenin pathways and the possible role of this crosstalk in the aggressiveness of glioblastoma. This study also provides a proof of principle that an inhibitor like anti IGFBP-2 scFv could be of importance for controlling invasive glioblastoma.

Made available in DSpace on 2016-06-02T19:22:08Z (GMT). No. of bitstreams: 1 4782.pdf: 15356873 bytes, checksum: 5c9a50ab5fc45152beb8cb72b03dcfec (MD5) Previous issue date: 2012-12-11 / Universidade Federal de Sao Carlos / The purpose of the present study was to examine the acute effects of resistance training (RT) on CD4+ and CD8+ T lymphocytes apoptosis (annexin V+) and migration (CX3CR1). Twelve subjects performed two RT sessions (3 sets of 9 exercises) with 1 min (Hyper-1) and 3 min (Hyper-3) of rest-interval length between sets and exercises. CD4+ and CD8+ cells count displayed no change following Hyper-1 and Hyper-3 (p > 0.05). There was an increase in the percentage of CD4+ positive for annexin V+ and CX3CR1+ immediately after and 24 h post Hyper-1 (p < 0.05). Percentage of CD4+ positive for annexin V+ increased 2 and 24 h post Hyper- 3, and decreased after CX3CR1+ for the same time-points (p < 0.05). There was an increase in CD8+ positive for annexin V+ and CX3CR1+ immediately after, 2 and 24 h post Hyper-1 and Hyper-3 (p < 0.05), while no differences were found between Hyper-1 and Hyper-3 (p > 0.05). Acute RT increase the apoptosis and migration of CD4+ and CD8+ lymphocytes even 24 h after exercise, with minimal effects of restinterval length. / O objetivo dos pesquisadores do presente estudo foi examinar os efeitos agudos do Exercício Resistido (ER) sobre a apoptose (Anexina V+) e a migração (CX3CR1) de linfócitos T CD4+ e CD8+. 12 sujeitos adultos realizaram duas sessões de ER (3 séries em 9 exercícios) com 1 minuto (Hiper-1) e 3 minutos (Hiper-3) de intervalo entre as séries e exercícios. Não foi observada alteração significativa na contagem celular de linfócitos CD4+ e CD8+ após os protocolos Hiper-1 e Hiper-3 (p > 0,05). Foi observado aumento no percentual de linfócitos T CD4+ positivos para anexina V+ e CX3CR1 imediatamente após e 24 horas após Hiper-1 (p < 0,05). A porcentagem de linfócitos T CD4+ positivos para anexina V+ aumentou 2 e 24 horas após Hiper-3 e diminuiu para CX3CR1 nos mesmos momentos (p < 0,05). Houve aumento nos linfócitos T CD8+ positivos para anexina V+ e CX3CR1+ imediatamente e 24 horas após os protocolos Hiper-1 e Hiper-3 (p < 0,05), enquanto que não foram observadas diferenças significativas entre Hiper-1 e Hiper-3 (p > 0,05). O ER aumenta marcadores celulares de apoptose e migração em linfócitos T CD4+ e CD8+ mesmo 24 horas após uma sessão aguda de exercício, com mínimo efeito da duração do intervalo de descanso entre as séries e exercícios.

O presente estudo comparou os efeitos da ativação e inibição do EGFR em duas linhagens de câncer de pulmão, cultivadas em monocamada ou esferoides. Os esferoides foram cultivados sem elementos de matriz extracelular. As células A549 e HK2 apresentaram, respectivamente, 3 e 6 cópias do gene ErbB1 por núcleo, embora a expressão de EGFR seja menor nas células HK2. A ativação de EGFR por EGF ou inibição por AG1478 não promoveu mudanças na proliferação celular. Entretanto, as células cultivadas em monocamada, estimuladas com EGF, exibiram alterações na disposição dos microfilamentos de actina e aumento na velocidade de migração celular. UO126 e LY294002 foram adicionados às culturas para inibir, respectivamente, as vias ERK e Akt. A linhagem A549, cultivada em monocamada, não apresentou envolvimento das vias de sinalização de ERK e Akt na migração celular induzida por EGF, mas foi observado o envolvimento dessas vias nos esferoides. Já a linhagem HK2 apresentou o envolvimento de Akt para promover a migração celular após estímulo com EGF nas duas formas de cultivo. / This study compared the effects of activation and inhibition of EGFR in two cell lines of lung cancer, grown in monolayer or spheroids. Spheroids were cultured without extracellular matrix components. HK2 and A549 cells showed, respectively, 3 and 6 ErbB1 gene copies per nucleus, while EGFR expression is lower in the HK2 cells. The activation by EGF or EGFR inhibition by AG1478 did not cause changes in cell proliferation. However, cells cultured in monolayers stimulated with EGF, showed changes in the arrangement of actin microfilaments and increased the speed of cell migration. UO126 and LY294002 were added to the cultures to inhibit, respectively, the ERK and Akt pathways. A549 cells grown in monolayer did not show involvement of ERK and Akt signaling pathways in the cell migration induced by EGF, but was observed involvement of such pathways in the spheroids. HK2 cells showed involvement of Akt to promote cell migration after EGF stimulation in monolayers and in spheroids.

La malignité des astrocytomes est établie sur base de critères morphologiques définis au sein de la classification de l’Organisation Mondiale de la Santé (OMS). Ce système de gradation, qui s’échelonne de I à IV, constitue actuellement l’outil pronostique le plus fiable. Par facilité, les cliniciens regroupent les astrocytomes de grade I (astrocytomes pilocytiques) et les astrocytomes diffus de grade II sous le terme d’« Astrocytomes de bas-grade » par opposition aux astrocytomes de haut-grade, constitués des astrocytomes anaplasiques (grade III) et des glioblastomes (GBM ;grade IV). Cette terminologie conduit à des prises en charge cliniques inadéquates car elle englobe des tumeurs très différentes en terme d’agressivité :les astrocytomes de grade I, majoritairement non infiltrants, non évolutifs et indolents et les astrocytomes diffus de grade II, toujours infiltrants et évolutifs, progressant systématiquement en astrocytomes de haut-grade et entraînant le plus souvent le décès prématuré du patient. Bien que ces tumeurs soient définies par la classification de l’OMS comme des entités clinicopathologiques distinctes, peu de données sont disponibles dans la littérature pour expliquer leurs particularités biologiques et la pratique quotidienne montre que les différencier peut être difficile. <p><p>Le but des études entreprises au cours de ce travail de thèse est d’apporter une contribution à la compréhension des mécanismes de tumorigenèse qui différencient l’astrocytome de grade I des astrocytomes diffus (grade II-IV), de manière à identifier des voies biologiques qui permettraient, au moins en partie, d’expliquer ces différences de comportement. <p><p>Au cours de la première partie de ce travail, nous avons caractérisé les profils d’expression génomique des astrocytomes de grade I et de grade II, en comparant les données d’expression de gènes (évaluées par des technologies de micropuces d’ADN) de travaux publiés entre 2000 et 2005. L’expression des gènes identifiés a été validée par des analyses de RT-PCR quantitative sur une série indépendante d’astrocytomes de grade I, II et IV. Les fonctions biologiques des protéines codées par chacun de ces gènes ont fait l’objet de recherches bibliographiques détaillées afin de proposer un modèle permettant d’approcher les différences de comportement de ces tumeurs. Cette analyse nous a permis d’identifier TIMP4 (tissue inhibitor of metalloproteinases 4) et IGFBP2 (insulin-like growth factor binding protein 2) comme gènes candidats pour améliorer la caractérisation biologique et clinique des astrocytomes de grade I par rapport aux astrocytomes diffus. TIMP4 et IGFBP2 codent respectivement pour un inhibiteur endogène des métalloprotéinases matricielles (MMPs) et une protéine de liaison capable d’inhiber l’action des « insulin-like growth factors » (IGFs, dont IGFI et IGFII), des facteurs impliqués dans la croissance et la migration des astrocytes normaux et tumoraux. <p><p>Sur base de la surexpression de TIMP4 et d’IGFBP2 dans les astrocytomes de grade I, en comparaison aux astrocytomes diffus de grade II, nous avons posé l’hypothèse suivante :« L’absence d’agressivité des astrocytomes de grade I, en comparaison aux astrocytomes diffus (grade II-IV) pourrait en partie être liée à l’inhibition par TIMP-4 de la protéolyse des complexes IGFBP2-IGFII au sein de ces tumeurs ». Cette protéolyse, qui diminue l’affinité d’IGFBP2 pour IGFII, pourrait contribuer à libérer IGFII dans la matrice extracellulaire (MEC), favoriser la liaison d’IGFII à son récepteur IGF-IR et stimuler la croissance et la migration des cellules astrocytaires tumorales. Pour tester cette hypothèse, nous avons réalisé différentes analyses biochimiques afin i) de caractériser les actions protéolytiques de MMP-2, MMP-9 et MT1-MMP sur le complexe IGFBP2-IGFII, ii) d’identifier la libération d’IGFII lors du clivage de ce complexe, et iii) d’étudier l’action inhibitrice de TIMP-4. A l’aide d’un modèle cellulaire in vitro (lignée astrocytaire tumorale LN229), nous avons ensuite observé l’influence de la protéolyse du complexe IGFBP2-IGFII sur la croissance et la motilité cellulaire. Cette étude a montré :(1) la protéolyse du complexe IGFBP2-IGFII par MMP-9, (2) l’inhibition partielle de cette protéolyse par TIMP-4, (3) la libération d’IGFII résultant de cette protéolyse et (4) les effets stimulants de la libération d’IGFII sur la croissance et la motilité des cellules LN229. Cette étude souligne le rôle important de la protéolyse des complexes IGFBP2-IGFII dans l’agressivité des astrocytomes diffus. Elle confirme les effets stimulants propres d’IGFII, d’IGFBP2 et de MMP-9 sur la motilité et/ou la croissance des cellules astrocytaires tumorales. Enfin, elle identifie un rôle inhibiteur potentiel de TIMP-4 sur la protéolyse du complexe IGFBP2-IGFII, qui pourrait contribuer à expliquer le caractère plus indolent des astrocytomes de grade I en comparaison aux astrocytomes diffus.<p><p>\ / Doctorat en Sciences médicales / info:eu-repo/semantics/nonPublished

Le glioblastome multiforme (GBM) est la tumeur cérébrale primaire la plus fréquente. Une dérégulation des voies de signalisation de l’EGFR et un fort potentiel invasif sont les caractéristiques principales du GBM. Malheureusement, les essais cliniques impliquant des thérapies anti-EGFR dans le traitement des GBM demeurent inefficaces. Nous avons précédemment montré que le récepteur de la fibronectine, l’intégrine α5β1, est associé avec un mauvais pronostic et une résistance des patients au temodal. Les intégrines peuvent coopérer avec les récepteurs aux facteurs de croissance et ainsi amplifier leur potentiel oncogénique. Ici, nous avons cherché à déterminer le rôle de l’intégrine α5 dans la résistance aux thérapies anti-EGFR. Utilisant la lignée U87 de GBM, on a dans un premier temps confirmé que l’activation de l’intégrine sous l’influence de la fibronectine, potentialisait la signalisation de l’EGFR. La perte d’expression d’α5 sensibilise les cellules U87 aux anti-EGFR (cetuximab, gefitinib) dans des essais de clonogénicité en soft agar. L’expression d’ α5 favorise la résistance aux 2 drogues lors de la migration cellulaire. Pour aller plus loin, nous avons développé un nouveau test basé sur la quantification de l’évasion cellulaire à partir d’une sphère tumorale. La perte d’ α5 augmente la sensibilité des cellules U87 à 2 TKI réversibles spécifiques de l’EGFR, gefitinib et erlotinib, mais n’a pas d’effet sur l’efficacité du lapatinib, un TKI irréversible ciblant EGFR, ErbB2, ErbB3 et ErbB4. Grâce à la microscopie confocale, nous avons montré l’effet important du gefitinib sur l’endocytose de l’intégrine et de l’EGFR. Ces résultats suggèrent que l’expression d’ α5 favorise la résistance aux TKI par l’activation des voies de signalisation des récepteurs ErbB ou en contrôlant le trafic membranaire de l’EGFR. On a aussi montré que pour favoriser l’adhésion cellulaire, l’intégrine α5 stimulait la fibrillogénèse. Dans les cellules migrant à distance de la sphère, l’intégrine α5 est strictement engagée dans des adhésions cellule-substrat contenant la protéine FAK activée. Nos résultats soulignent le rôle central du couple fibronectine/ intégrine α5 dans l’invasivité du GBM et la résistance aux thérapies anti-EGFR. / Glioblastoma multiforme (GBM) is the most common primary brain tumor. Alteration of the EGFR pathway and high invasive potential are hallmarks of GBM. Unfortunately, trials using anti-EGFR therapies for the treatment of GBM reveal limited efficacy. We previously showed that overexpression of the fibronectin receptor, α5β1 integrin, is associated with a poor prognosis for patients and is responsible for chemoresistance to temodal. Integrins can cross-talk with growth factor receptors and amplified their oncogenic activity. Here, we sought to determine the potential role of α5 integrin in resistance to anti-EGFR therapy. Using U87 GBM cell line, we first confirmed that fibronectin-mediated integrin activation potentiated EGFR signaling. Loss of α5 integrin expression sensitized U87 cells to anti-EGFR drugs (cetuximab, gefitinib) in soft agar clonogenic assay. α5 expression can trigger resistance to both drugs on cell migration. To go further, we developed a new assay based on the quantification of cell evasion from tumor spheroids. α5 depletion increased U87 cell sensitivity to gefitinib and erlotinib, 2 EGFR-selective reversible TKI, but had not effect on lapatinib efficacy, an irreversible TKI that target EGFR, ErbB2, ErbB3 and ErbB4. Confocal microscopy revealed a strong impact of gefitinib on EGFR and integrin endocytosis. These results suggested that α5 expression may trigger resistance to TKI either by activating ErbB pathways or by controlling EGFR membrane trafficking. We also showed that to promote cell adhesion, α5 integrin stimulated fibronectin fibrillogenesis. As cells moved away from the spheroids, α5 became strictly engaged in cell-substratum adhesion sites where it recruited activated FAK. Our work highlights the pivotal role of fibronectin/α5β1 integrin in invasivity of GBM and resistance to anti-EGFR drugs.

La leptospirose est une zoonose causée par les bactéries du genre Leptospira. Elle touche près de 1 million d'individus par an dans le monde entier et sévit à l'état endémique dans les pays au climat tropical tel que La Réunion. Les manifestations habituelles sont variables d'un individu à l'autre et englobent une simple fièvre jusqu'aux défaillances poly-viscérales avec mortalité dans 5 à 10% des cas. Sa physiopathologie est encore mal comprise, en particulier la part que joue une réponse immunitaire inappropriée dans la genèse des manifestations graves qui surviennent en quelques heures, et avant la mise en place d'une réponse immunitaire adaptative propre à éliminer le microorganisme. Si l'échappement de la bactérie au système du complément est bien documenté, le rôle des acteurs cellulaires du système immunitaire inné reste à étayer. Notre étude avait donc pour objectif d'explorer l'immunopathologie de la leptospirose humaine dans la phase initiale de l’infection. Notre méthodologie s'est appuyée principalement sur des analyses quantitatives et qualitatives des acteurs cellulaires du système immunitaire inné à partir de prélèvements sanguins en phase précoce de la maladie, et comparaison avec la phase de convalescence et des sujets contrôles. Dans un premier temps nous avons montré qu'une population particulière de lymphocytes T impliquée dans la réponse immune innée, les lymphocytes Tγδ, avaient un taux abaissé et que cette baisse était corrélée à la charge bactérienne ainsi qu'à l’intensité de l'atteinte hépatique classiquement retrouvée lors de la leptospirose. Dans un deuxième temps, nous avons analysé les polynucléaires neutrophiles circulants dont le taux augmente d’autant plus que la maladie est sévère, mais sans pour autant présenter de modification de certains marqueurs d’activation ou de recrutement tissulaire (CD15, CD11b, CD182). Une des principales chimiokines des neutrophiles, l'interleukine 8, était à taux peu élevés. Les derniers travaux concernent les principales formes solubles issues des molécules membranaires impliquées dans le processus de recrutement/diapédèse leucocytaire. Nous retrouvons de manière isolée une forte élévation des formes solubles d'E-sélectine et ICAM-1 qui sont notamment exprimées par les cellules endothéliales. Ces augmentations n'étaient pas corrélées aux marqueurs de gravité de la maladie. La signification biologique de cette élévation n’est pas encore connue lors de la leptospirose. L'ensemble de nos données permet d’apporter des informations nouvelles sur des acteurs du système immunitaire inné présents dans le compartiment vasculaire lors de la leptospirose humaine. Cette réponse immunitaire semble inadaptée pour permettre une clairance du pathogène au stade de dissémination hématogène. / Leptospirosis is a bacterial zoonosis caused by Leptospira and affecting 1 million people each year worldwide and mainly in tropical areas such as Reunion Island. Usual presentations encompass flu-like syndrome to multiorgan failure with mortality rate between 5 to 10%. To date, pathophysiology in humans is poorly understood, notably the capacity of innateimmunity to mount a robust response to clear pathogen or to induce tissue damages and contributing to disease severity. Our study aimed at assessing the role of innate immune cells and molecules within the first days of leptospiral infection.Using blood samples, we performed quantitative and qualitative assessment of circulating innate immune cells from leptospirosis cases and healthy controls. The first study explored the levels of gamma-delta T-cells (γδT-cells), a subset of unconventional T cells with innate immune functions. Gamma-delta T cells were found deeply decreased and levels wereinversely correlated to bacterial burden and liver damage. The second study focused on membrane bound receptors indicative of activation and tissue migration ability of neutrophil polymorphonuclear cells: CD15, CD11b, and CD182. Although neutrophil rates were high in leptospirosis cases, the levels of studied receptors were either lower (CD15) or identical to healthy controls (CD11b, CD182). In addition, only low levels of interleukin-8, a key chemokine for neutrophils, was detected in patients. Lastly, we ascertained the plasmatic levels of several shed cell adhesion molecules notably expressed by endothelial cells. The levels of soluble E-selectin and ICAM-1 were significantly increased compared to controls, while P-selectin level was lower. We did not find any correlation with disease severity or organ failure. This finding indicates that endothelial cell may be activated but further experiments are warranted to explain the functional impact of our findings. Altogether, our results add to the field of knowledge of leptospirosis pathophysiology, and in particular the implication of key innate immune cells at the stage of plasmatic bacterial dissemination. Our findings will support the view that there is an inappropriate immune response to Leptospira.

Abstract Transgenic mice were used to evaluate the roles of collagens XV and XVIII in retinal vessel development and to examine the roles of collagen XV and laminin α4 in peripheral nerve development and function. Also, in vitro methods were used to study the functions of recombinant, full-length human collagen XV produced in insect cells. The lack of collagen XVIII alone was found to result in overproliferation of astrocytes in the mouse retina and deficient vascularization of the retina, which was ultimately rescued by the persistent hyaloid vessels. VEGF mRNA expression was appropriately regulated in the retina of the collagen XVIII deficient mice, which also showed reduced susceptibility to oxygen-induced neovascularization. Lack of collagen XV alone had no obvious effect on the mouse eye, but an abnormal migration of astrocytes onto the persistent hyaloid vessels could be seen in mice lacking both collagens XVIII and XV. Recombinant full-length human collagen XV was seen in rotary shadowing EM as an extended protein with numerous kinks and a globular domain at its N-terminus. The mean length of the molecules was 241 nm and they had a tendency to form aggregates. Collagen XV attaches to the collagen binding region of fibronectin and to a lesser extent to vitronectin and laminin. It was rapidly bound to cultured cells with a staining pattern co-localizing with fibronectin. Collagen XV was also found to inhibit the adhesion and migration of cells in vitro. Lack of collagen XV in mice was found to result in ultrastructural abnormalities in the sciatic nerves, such as polyaxonal myelination and more loosely packed C-fibres, mild impairment of BM assembly and mild motor dysfunction with a lower sensory nerve conduction velocity. Polyaxonal myelination and a failure in the segregation of axons were evident in laminin α4 null mice, which also had diminished amounts of C-fibres, BM abnormalities, diminished myelin and a greater myelin period compared with wild-type mice. They performed poorly in the round beam test and showed diminished compound muscle action potentials. A simultaneous lack of collagen XV and laminin α4 resulted in a permanent defect in the segregation of axons and C-fibre development. The performance of the double null mice on the round beam was poor relative to the other genotypes. / Tiivistelmä Tässä väitöskirjatyössä on tutkittu kollageenien XV ja XVIII merkitystä silmän verkkokalvon verisuonituksen kehittymiselle sekä kollageeni XV:n ja laminiini α4:n merkitystä ääreishermon kehittymiselle ja toiminnalle käyttäen hyväksi muuntogeenisiä hiiriä. Lisäksi tässä työssä on käytetty in vitro –menetelmiä hyönteissoluissa yhdistelmä-DNA-tekniikalla tuotetun kollageeni XV:n toiminnan tutkimiseksi. Kollageeni XVIII:n puutteen todettiin johtavan verkkokalvon astrosyyttien määrän lisääntymiseen sekä verkkokalvon suonituksen kehittymiseen epänormaalilla tavalla lasiaissuonista, jotka eivät olleetkaan hävinneet kehityksen aikana. VEGF:n lähetti-RNA:n ilmentyminen oli asianmukaisesti säädelty eri verkkokalvon alueilla kollageeni XVIII:n suhteen poistogeenisillä hiirillä, joilla kehittyi myös vähemmän uudissuonia matalalle hapen osapaineelle altistamisen jälkeen. Kollageeni XV:n puute ei johtanut havaittaviin muutoksiin silmässä, mutta molempien kollageenien XV ja XVIII puuttuessa havaittiin silmässä epänormaalia astrosyyttien soluvaellusta lasiaissuonten päälle. Tässä väitöskirjatyössä osoitetaan, että yhdistelmä-DNA-tekniikalla tuotettu kokopitkä ihmisen kollageeni XV näytti elektronimikroskopiassa pitkältä molekyyliltä, jonka pituus oli keskimäärin 241 nm ja joka sitoutui helposti toisiin kollageeni XV -molekyyleihin. Kollageeni XV sitoutuu fibronektiinin kollageenia sitovaan osaan sekä vitronektiiniin ja laminiiniin. Viljeltyihin soluihin kollageeni XV sitoutui siten, että vasta-ainevärjäyksellä todettiin sen paikallistuvan samoille alueille fibronektiinin kanssa. Kollageeni XV:n todettiin myös vähentävän solujen kiinnittymistä ja liikkumista. Hiirissä kollageeni XV:n puutoksen todettiin johtavan iskiahermoissa polyaksonaaliseen myelinisaatioon, C-säikeiden lievään kehityshäiriöön, tyvikalvon koostumuksen häiriöön, lieviin motorisiin vaikeuksiin ja matalampaan tuntohermojen johtonopeuteen. Laminiini α4 –puutteisilla hiirillä oli todettavissa myös polyaksonaalista myelinisaatiota ja lisäksi häiriö aksonien erottelussa. Niiden hermoista löytyi myös tyvikalvon epämuodostumia, vähemmän myeliiniä ja C-säikeitä sekä suuremmat myeliinijaksot verrattuna villityypin hiiriin. Ne selviytyivät huonosti kävelytestissä ja niiden lihasten aktiopotentiaalit olivat pienemmät kuin kontrollihiirillä. Samanaikainen kollageeni XV:n ja laminiini α4:n puutos johti pysyvään aksonien erottelun ja C-säikeiden kehittymisen häiriöön. Kävelytestissä tuplapoistogeeniset hiiret selviytyivät huonoiten muihin genotyyppeihin verrattuna.

Micro (mi)RNAs have recently been found to play an important role in cancer biology. In order to further understand how miRNAs affect prostate tumour progression, we evaluated miRNA expression in two invasive prostate tumour lines, PC3 and DU145. We then focused our evaluation on a novel miRNA, miR-105, whose levels were significantly decreased in both tumour cell lines as compared to normal prostate epithelial cells. As miR-105 levels were reduced in prostate tumour cell lines, we restored its expression following transfection of cells with mimic constructs to over-express miR-105 in both cell lines, in order to determine its effect on various tumourigenic properties. Over-expression caused decreased tumour cell proliferation, anchorage-independent growth and invasion in vitro and inhibited tumour growth in vivo. We further identified CDK6 as a putative target of miR-105, which likely contributed to its inhibition of tumour cell growth. Our results suggest that miR-105 inhibits tumour cell proliferation and may be an interesting target to regulate tumour growth or potentially used as a biomarker to differentiate between less and more aggressive tumours in patients.

Les cellules dendritiques (DCs) patrouillent les tissus périphériques à la recherche de dangers potentiels en se déplaçant à travers les tissus et en incorporant de grande quantité de matériel extracellulaire. Cet événement précoce de la réponse immunitaire adaptative est susceptible de déterminer l'amplitude et la qualité de l'activation des lymphocytes T et B. De ce fait, les DCs pourraient avoir besoin d'orchestrer leur motilité et leur fonction de capture des antigènes afin d'initier un réponse immunitaire efficace et adaptée. Afin d'étudier les mécanismes responsables de l'optimisation de l'échantillonnage des tissus par les DCs, nous avons suivi leur migration et leur capacité à capturer des antigènes dans des chambres micro-fluidiques contenant des canaux étroits qui permettent de reproduire l'espace confiné des tissus périphériques. De manière surprenante, nous avons découvert que la migration des DCs et leur aptitude à accumuler des antigènes sont des fonctions antagonistes et dépendent de l'activité du moteur moléculaire Myosine II. Nous avons observé que les DCs se déplacent en alternant des phases rapides au cours desquelles la Myosine II est distribuée de manière asymétrique à l'arrière des cellules, et des phases plus lentes pendant lesquelles la Myosine II est enrichie à l'avant. Les enrichissements transitoires de Myosine II à l'avant des DCs dépendent de l'association de la Myosine II avec la chaîne invariante associée au CMH-II (Ii). Ces évenements favorisent l'absorption d'antigènes et leur transport dans les compartiments endolysosomaux. Des expériences menées avec une pince optique nous ont permis de montrer que l'activité de la Myosine II à l'avant des cellules génère des forces mécaniques qui induisent le transport des vésicules vers l'intérieur de la cellule, probablement en modulant le flux rétrograde d'actine. Ainsi, au cours de cette thèse, nous avons montré que la Myosine II était nécessaire à la fois pour la migration cellulaire et la capture d'antigènes, établissant un mécanisme moléculaire qui permet de coordonner ces deux processus dans le temps et l'espace. Nous proposons que l'alternance de phases de haute mobilité et de phases d'arrêt associées à la capture d'antigènes confère aux DCs une stratégie de recherche intermittente qui leur permettrait d'optimiser la surveillance des tissus périphériques. / Dendritic cells (DCs) patrol peripheral tissues in search for potential dangers by actively crawling and internalizing extracellular materiel. This initial event of an adaptive immune response is likely to determine the magnitude and quality of T cell and B cell immunity. Therefore, DCs might need to tightly orchestrate their migration and their antigen uptake function in order to mount an efficient and adapted immune response. To investigate the mechanisms responsible for the optimization of tissues sampling by DCs, we monitored their migration and their ability to capture antigens in micro-fluidic chambers containing narrow channels that mimic the confined space of peripheral tissues. Surprisingly, we found that cell migration and antigen accumulation in endolysosomes are antagonistic, both relying on the activity of the motor protein Myosin II. We observed that DCs alternate between phases of fast motility during which Myosin II is asymmetrically distributed at the cell rear, and phases of slow motility during which Myosin is enriched at the cell front. Transient Myosin II enrichments at the leading edge depends on its association with the MHC-II associated Invariant Chain (Ii). These events promote antigen uptake and arrival in endolysosomal compartments. Using optical tweezers, we further showed that Myosin II activity at the leading edge generates mechanical forces that drive vesicles transport toward the cell body probably through the modulation of F-actin retrograde flow. Thus, during my PhD, we have shown that Myosin II is required for both migration and antigen capture, providing a molecular mechanism to couple these two processes and allow their coordination in time and space. We propose that alternation between phases of fast motility and phases of low motility associated with efficient antigen capture imposes an intermittent search behavior on DCs, which might be optimal for environment patrolling.